SABCS 2024盛幕将启,中国之声唱响全球!

作者:肿瘤瞭望   日期:2024/11/7 10:54:28  浏览量:95

肿瘤瞭望版权所有,谢绝任何形式转载,侵犯版权者必予法律追究。

第47届圣安东尼奥乳腺癌研讨会(SABCS)将于当地时间2024年12月10日至13日在美国得克萨斯州圣安东尼奥举行。日前,官网已公布摘要题目,肿瘤瞭望特将General Session、Poster Spotlight Sessions和Year in Review等环节中国专家报告内容进行汇总,以飨读者。

编者按:第47届圣安东尼奥乳腺癌研讨会(SABCS)将于当地时间2024年12月10日至13日在美国得克萨斯州圣安东尼奥举行。日前,官网已公布摘要题目,肿瘤瞭望特将General Session、Poster Spotlight Sessions和Year in Review等环节中国专家报告内容进行汇总,以飨读者。
 
General Session 1
 
时间:12月11日9:15–11:30 am
地点:Hall 1
 
GS1-03:Pyrotinib or placebo in combination with trastuzumab and docetaxel for untreated HER2-positive metastatic breast cancer(mBC):prespecified final analysis of progression-free survival(PFS)of the phase 3 PHILA trial.
吡咯替尼或安慰剂联合曲妥珠单抗和多西他赛用于未接受过治疗的HER2阳性转移性乳腺癌(mBC):III期PHILA试验预设的无进展生存期(PFS)最终分析
讲者:徐兵河(中国医学科学院肿瘤医院)
 
GS1-04:HER2-Directed Antibody-Drug Conjugate SHR-A1811 in the Neoadjuvant Treatment of HER2-positive Early Breast Cancer:a Prospective,Randomized,Open-label,Phase 2 Trial.
靶向HER2的抗体-药物偶联物SHR-A1811用于HER2阳性早期乳腺癌的新辅助治疗:一项前瞻性、随机、开放标签的2期试验
讲者:李俊杰(复旦大学附属肿瘤医院)
 
General Session 3
 
时间:12月13日9:00–11:45 am
地点:Hall 1
 
GS3-06:Neoadjuvant camrelizumab plus chemotherapy(chemo)for early or locally advanced triple-negative breast cancer(TNBC):a randomized,double-blind,phase 3 trial.
卡瑞利珠单抗联合化疗(chemo)新辅助治疗早期或局部晚期三阴性乳腺癌(TNBC):一项随机、双盲、3期试验
讲者:邵志敏(复旦大学附属肿瘤医院)
 
Concurrent Poster Spotlight Sessions 1,3-5,7

▌Session 1:New Insights into Immune Biomarkers(免疫生物标志物的新见解)
 
时间:12月11日7:00–8:30 am
地点:Room 221ABC
主持人:David Rimm,Yale University
 
PS1-03:Prediction of Prognosis and Efficacy of Neoadjuvant Therapy in HER2-Positive Breast Cancer Patients Based on Tertiary Lymphoid Structures.
基于三级淋巴结构预测HER2阳性乳腺癌患者的预后和新辅助治疗的疗效
讲者:张克兢(中南大学湘雅医院)
 
▌Session 3:Highlights on Novel Therapeutics(新型治疗亮点)
 
时间:12月11日7:00–8:30 am
地点:Stars at Night 1-2
主持人:Sara Tolaney,Dana-Farber Cancer Institute
 
PS3-01:Tislelizumab plus sitravatinib and nab-paclitaxel in patients with untreated locally recurrent or metastatic triple negative breast cancer(TNBC):updated efficacy and safety results.
替雷利珠单抗+sitravatinib+白蛋白结合型紫杉醇治疗未经治疗的局部复发或转移性三阴性乳腺癌(TNBC):最新的疗效和安全性结果
讲者:Xiyu Liu(复旦大学附属肿瘤医院)
 
PS3-02:Induction of Cisplatin/abraxane/pembrolizumab followed by pembrolizumab±Olaparib Maintenance in triple-negative Metastatic breast cancer patients(COMPLEMENT)–A Randomized,Open-label,Phase II Study.
COMPLEMENT:一项随机、开放标签的II期研究,在转移性三阴性乳腺癌患者中,采用顺铂/白蛋白结核型紫杉醇/帕博利珠单抗诱导治疗,后续以帕博利珠单抗±奥拉帕利进行维持治疗
讲者:胡夕春(复旦大学附属肿瘤医院)
 
PS3-05:Evaluation of the safety and efficacy of ivonescimab in combination with chemotherapy as first-line(1L)treatment for triple-negative breast cancer(TNBC).
评估ivonescimab联合化疗作为三阴性乳腺癌(TNBC)一线(1L)治疗的安全性和有效性
讲者:欧阳取长(湖南省肿瘤医院)
 
PS3-08:Interim Overall Survival of Patients with Locally Advanced or Metastatic Triple-Negative Breast Cancer treated wtih First Line PM8002/BNT327 in Combination with Nab-Paclitaxel in Phase Ib/II Study.
Ib/II期研究中,PM8002/BNT327联合白蛋白结合型紫杉醇一线治疗局部晚期或转移性三阴性乳腺癌患者的中期总生存
讲者:吴炅(复旦大学附属肿瘤医院)
 
▌Session 4:Prediction of Chemotherapy Response(化疗疗效预测)
 
时间:12月11日7:00–8:30 am
地点:Stars at Night 3-4
主持人:Sherene Loi,Peter Macallum Cancer Centre
 
PS4-08:The tumor heterogeneous overexpressed CD155 promotes treatment resistance in HER2-positive breast cancer through immune microenvironment modulation.
肿瘤异质性CD155过表达通过调节免疫微环境促进HER2阳性乳腺癌的治疗抵抗
讲者:Yi Zhang(复旦大学附属肿瘤医院)
 
Concurrent Poster Spotlight Sessions 2,6,8,9 and 15
 
▌Session 2:Personalizing CDK 4/6 inhibitor therapy for patients with Metastatic Breast Cancer:Survival,QOL and biomarkers(转移性乳腺癌患者的个体化CDK 4/6抑制剂治疗:生存期、生活质量和生物标志物)
 
时间:12月12日7:00–8:30 am
地点:Hemisfair Ballroom 1-2
主持人:Lisa Carey,Lineberger Comprehensive Cancer Center University of North Carolina
 
PS2-01:Dalpiciclib versus placebo in combination with letrozole or anastrozole as first-line treatment for women with HR+/HER2-advanced breast cancer:prespecified final analysis of progression-free survival of the phase 3 DAWNA-2 trial.
3期DAWNA-2研究预设的无进展生存最终分析:达尔西利vs安慰剂联合来曲唑或阿那曲唑作为HR+/HER2-晚期乳腺癌女性患者一线治疗
讲者:徐兵河(中国医学科学院肿瘤医院)
 
PS2-02:Tibremciclib(BPI-16350)plus fulvestrant versus placebo plus fulvestrant for patients with HR+/HER2-advanced breast cancer after progressing on endocrine therapy:Updated analysis of the phase III study.
在内分泌治疗进展后的HR+/HER2-晚期乳腺癌患者,Tibremciclib(BPI-16350)联合氟维司群对比安慰剂联合氟维司群的疗效:III期研究的更新分析
讲者:胡夕春(复旦大学附属肿瘤医院)
 
PS2-06:First-line(1L)ribociclib(RIB)+endocrine therapy(ET)vs combination chemotherapy(combo CT)in clinically aggressive HR+/HER2-advanced breast cancer(ABC):a subgroup analysis of RIGHT Choice by intrinsic subtype&gene&signature expression.
一线(1L)瑞波西利(RIB)+内分泌治疗(ET)vs联合化疗(combo CT)治疗临床侵袭性HR+/HER2-晚期乳腺癌(ABC):基于内在亚型、基因及特征表达的RIGHT Choice研究亚组分析
讲者:卢彦伸(中国台湾大学医学院附属医院)
 
PS2-10:Integrating ctDNA and Tumor Fraction Features for Deciphering Molecular Response and Resistance Mechanism to Endocrine Therapy and CDK4/6 Inhibition in Advanced HR-positive Metastatic Breast Cancer.
整合ctDNA和肿瘤组分特征以解析晚期激素受体阳性转移性乳腺癌对内分泌治疗和CDK4/6抑制剂的分子应答及耐药机制
讲者:Hao Liao(北京大学肿瘤医院)
 
▌Session 8:Novel HER2 Therapeutics(新型HER2治疗)
 
时间:12月12日7:00–8:30 am
地点:Stars at Night 1-2
主持人:Ian Krop,Yale School of Medicine
 
PS8-01:ZN-1041,a potential best-in-class BBB Penetrable HER2 Inhibitor,has high antitumor activity in patients with Breast Cancer with CNS Metastases.
ZN-1041是一种具有潜力的同类最佳血脑屏障(BBB)可穿透性HER2抑制剂,在中枢神经系统(CNS)转移乳腺癌患者中展现出高抗肿瘤活性
讲者:马飞(中国医学科学院肿瘤医院)
 
PS8-02:A Phase 1 study Evaluating the Safety,Efficacy and Pharmacokinetics of TL938 in HER2-Positive Patients with Advance Solid Tumors.
一项评价TL938治疗HER2阳性晚期实体瘤患者的安全性、疗效和药代动力学的1期研究
讲者:石远凯(中国医学科学院肿瘤医院)
 
PS8-05:ACE-Breast-08:a phase I study of ARX788,a novel anti-HER2 antibodydrug conjugate,in patients with TKI pretreated HER2 positive advanced breast cancer.
ACE-Breast-08:一项I期研究,评估新型抗HER2抗体-药物偶联物ARX788在TKI预治疗的HER2阳性晚期乳腺癌患者中的疗效
讲者:王晓稼(浙江省肿瘤医院)
 
PS8-06:A randomized,open-label phase III study comparing disitamab vedotin(an anti-HER2 monoclonal antibody-MMAE conjugate)with lapatinib plus capecitabine in patients with HER2-positive,advanced breast cancer with liver metastasis.
一项随机、开放标签的III期研究,在伴肝转移的HER2阳性晚期乳腺癌患者中比较维迪西妥单抗(一种抗HER2单克隆抗体-MMAE偶联物)联合拉帕替尼联合卡培他滨的治疗疗效
讲者:王佳玉(中国医学科学院肿瘤医院)
 
PS8-07:Efficacy and Safety of GQ1005,a Promising HER2-ADC,in Patients with Metastatic HER2-Positive Breast Cancer.
GQ1005(一种很有前景的HER2-ADC)治疗转移性HER2阳性乳腺癌患者的疗效和安全性
讲者:王碧芸(复旦大学附属肿瘤医院)
 
PS8-08:Efficacy and safety of SHR-A1811,an anti-HER2 antibody-drug conjugate(ADC),in 391 heavily pretreated multiple solid tumors with HER2-expression or mutations:a global,multi-center,first-in-human,phase 1 study.
SHR-A1811是一种抗HER2抗体-药物偶联物(ADC),在391例既往接受过大量治疗且有HER2表达或突变的多种实体瘤中,SHR-A1811的疗效和安全性:一项全球性、多中心、首次人体1期研究
讲者:姚和瑞(中山大学孙逸仙纪念医院)
 
Concurrent Poster Spotlight Sessions 10-14
 
▌Session 11:Imaging to Guide Breast Cancer Treatment–Molecular Imaging and AI(影像学指导乳腺癌治疗——分子影像学和人工智能)
 
时间:12月13日7:00–8:30 am
地点:Hemisfair Ballroom 1-2
主持人:David Mankoff,Perelman School of Medicine University of Pennsylvania
 
PS11-08:MRI improves multi-modal AI system for breast cancer diagnosis and prognosis.
MRI提高了多模态AI系统对乳腺癌的诊断和预后判断
讲者:Yanqi Xu(中国药科大学)
 
▌Session 12:Immunobiology Impact on Therapeutic Efficacy(免疫生物学对治疗效果的影响)

时间:12月13日7:00–8:30 am
地点:Room 221ABC
主持人:Lajos Pusztai,Yale School of Medicine,New Haven,Connecticut
 
PS12-04:HDACi combined with anthracycline elicits interactions between MHC-II+triple-negative breast cancer and CD69+CD4+Trm orchestrating synergistic immunotherapy.
HDACi联合蒽环类药物引发MHC-II+三阴性乳腺癌与CD69+CD4+Trm协同免疫治疗之间的相互作用
讲者:Zehao Wang(复旦大学附属肿瘤医院)
 
▌Session 14:Brain Metastasis(脑转移)
 
时间:12月13日7:00–8:30 am
地点:Stars at Night 3-4
主持人:William Gradishar,Northwestern University Feinberg School of Medicine,Chicago,Illinois
 
PS14-02:A Prospective Phase II Trial of Hypofractionated Stereotactic Radiotherapy(FSRT)for Patients with 1-10 Brain Metastases from Breast Cancer.
一项前瞻性II期试验,1~10个乳腺癌脑转移患者采用大分割立体定向放疗(FSRT)
讲者:Jin Meng(上海交通大学附属第六人民医院)
 
PS14-03:Updated analyses from a Phase I study of the brain-penetrant oral SERD-SIM0270 in patients with ER-positive,HER2-negative advanced breast cancer.
脑渗透性口服SERD-SIM0270治疗ER阳性/HER2阴性晚期乳腺癌患者的I期研究的最新分析
讲者:张清媛(哈尔滨医科大学附属肿瘤医院)
 
PS14-04:SIM0270,a brain-penetrant oral SERD,in combination with everolimus in patients with ER+/HER2-advanced breast cancer:the phase Ib study.
SIM0270,一种脑渗透性口服SERD,联合依维莫司在ER+/HER2-晚期乳腺癌患者中的Ⅰb期研究
讲者:张剑(复旦大学附属肿瘤医院)
 
Year in Review
 
时间:12月13日3:00–5:00 pm
地点:Stars at Night 1-2
主持人:Moderators:Carlos Arteaga,UT Southwestern Medical Center,Dallas,Texas;and Virginia Kaklamani,UT Health Mays Cancer Center,San Antonio,Texas
 
Early Breast Cancer Updates
早期乳腺癌最新进展
讲者:Janice Tsang(中国香港大学)

 

 

版面编辑:张靖璇new  责任编辑:无医学编辑

本内容仅供医学专业人士参考


乳腺癌

分享到: 更多